The phase 1 study of CWP232291 in AML/MDS had acceptable toxicity, reduced survivin expression (β-catenin target gene), but had only minimal/modest overall efficacy indicating its deployment to eradicate Wnt signalling active LSCs may need combining with other agents [131]. This evidence concerns the gene BIRC5 and acute myeloid leukemia.